Magnetic Resonance & Optical Spectroscopy Validation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01827527|
Recruitment Status : Recruiting
First Posted : April 9, 2013
Last Update Posted : February 15, 2019
|Condition or disease|
|Validation Studies Magnetic Resonance Spectroscopy|
Primary Study Objective:
To evaluate the reproducibility of acquiring multi-nuclear data on a new 3T Philips Magnet in conjunction with Optical Spectroscopy.
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||Development and Validation of 31P Magnetic Resonance and Optical Spectroscopy for the Characterization of ATP in Whole Body Human Applications|
|Study Start Date :||March 2013|
|Estimated Primary Completion Date :||March 2023|
|Estimated Study Completion Date :||March 2023|
This is a protocol development study, with no interventions or treatments.
- Rate of phosphocreatine (PCr) decay [ Time Frame: Hour 2 ]
The PCr decay (rate of PCr breakdown during ischemia) will be used to measure the ATP turnover rates (ATPase).
After the baseline is established, the volunteer will be asked to perform contractions of the quadriceps (by slight kicking) for up to 45 seconds.
. After kicking is stopped, the volunteer will remain still for an additional 5 minutes in order to allow the PCr peak to return to baseline. The ATPase experiment will also be performed by acquiring 31P Spectra every 6 seconds.
- Rate of oxygen uptake [ Time Frame: Hour 2 ]OS will be used to measure the oxygen (O2) uptake by following the rate of Hb-O2 and Mb-O2 deoxygenation during ischemia. The rate of the depletion of these O2 stores measures the rate of O2 uptake by the mitochondria. The Horbia Jobin Yvon optical system will be used. The OS acquisition procedure has been thoroughly described by Marcinek et.al
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01827527
|Contact: Recruitment Department||(407) firstname.lastname@example.org|
|United States, Florida|
|Translational Research Institute for Metabolism and Diabetes||Recruiting|
|Orlando, Florida, United States, 32804|
|Contact: Recruitment Department 407-303-7100 email@example.com|
|Principal Investigator: Heather Cornnell, PhD|
|Principal Investigator:||Steven R. Smith, MD||Translational Research Institute for Metabolism and Diabetes|
|Principal Investigator:||Heather Cornnell, PhD||Translational Research Institute for Metabolism and Diabetes|